Medications for comorbid conditions may affect cognition in Alzheimer's disease (AD).
Objective
To explore the association between common medications and cognition, measured with the Mini-Mental State Examination.
Methods
Cohort study including persons with AD from the Swedish Registry for Cognitive/Dementia Disorders (SveDem). Medications were included if they were used by ≥5% of patients (26 individual drugs). Each follow-up was analyzed independently by performing 100 Monte-Carlo simulations of two steps each 1) k-means clustering of patients according to Mini-Mental State Examination at follow-up and its decline since previous measure, and 2) Identification of medications presenting statistically significant differences in the proportion of users in the different clusters.
Results
15,428 patients (60.38% women) were studied. Four clusters were identified. Medications associated with the best cognition cluster (relative to the worse) were atorvastatin (point estimate 1.44 95% confidence interval [1.15–1.83] at first follow-up, simvastatin (1.41 [1.11–1.78] at second follow-up), warfarin (1.56 [1.22–2.01] first follow-up), zopiclone (1.35 [1.15–1.58], and metformin (2.08 [1.35–3.33] second follow-up. Oxazepam (0.60 [0.50–0.73] first follow-up), paracetamol (0.83 [0.73–0.95] first follow-up), cyanocobalamin, felodipine and furosemide were associated with the worst cluster. Cholinesterase inhibitors were associated with the best cognition clusters, whereas memantine appeared in the worse cognition clusters, consistent with its indication in moderate to severe dementia.
Conclusions
We performed unsupervised clustering to classify patients based on their current cognition and cognitive decline from previous testing. Atorvastatin, simvastatin, warfarin, metformin, and zopiclone presented a positive and statistically significant associations with cognition, while oxazepam, cyanocobalamin, felodipine, furosemide and paracetamol, were associated with the worst cluster.
JørgensenIFAguayo-OrozcoALademannM, et al.Age-stratified longitudinal study of Alzheimer’s and vascular dementia patients. Alzheimers Dement2020; 16: 908–917.
2.
PetekBHäbelHXuH, et al.Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. Alzheimers Res Ther2023; 15: 220.
3.
Loera-ValenciaREroliFGarcia-PtacekS, et al.Brain renin-angiotensin system as novel and potential therapeutic target for Alzheimer’s disease. Int J Mol Sci2021; 22: 10139.
4.
FeldmanHHDoodyRSKivipeltoM, et al.Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. Neurology2010; 74: 956–964.
5.
PetekBVilla-LopezMLoera-ValenciaR, et al.Connecting the brain cholesterol and renin–angiotensin systems: potential role of statins and RAS-modifying medications in dementia. J Intern Med2018; 284: 620–642.
6.
SanoMBellKLGalaskoD, et al.A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology2011; 77: 556–563.
7.
TampiRRTampiDJBalachandranS, et al.Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis2016; 7: 229–245.
8.
Massot MesquidaMTristany CasasMFranzi SisóA, et al.Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients. BMC Geriatr2019; 19: 7.
KalarIXuHSecnikJ, et al.Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study. J Intern Med2021; 289: 508–522.
11.
XuHGarcia-PtacekSSecnikJ, et al.Changes in drug prescribing practices are associated with improved outcomes in patients with dementia in Sweden: experience from the Swedish Dementia Registry 2008-2017. J Am Med Dir Assoc2021; 22: 1477–1483.e3.
12.
SubicACermakovaPNorrvingB, et al.Management of acute ischaemic stroke in patients with dementia. J Intern Med2017; 281: 348–364.
13.
PetekBXuHVilla-LopezM, et al.Statins, risk of death and ischemic stroke in patients with dementia: a registry-based observational cohort study. Curr Alzheimer Res2020; 17: 881–892.
14.
CoombesCELiuXAbramsZB, et al.Simulation-derived best practices for clustering clinical data. J Biomed Inform2021; 118: 103788.
15.
AlashwalHEl HalabyMCrouseJJ, et al.The application of unsupervised clustering methods to Alzheimer’s disease. Front Comput Neurosci2019; 13: 31.
16.
WuYDuanHDuS. Multiple fuzzy c-means clustering algorithm in medical diagnosis. Technol Health Care2015; 23: S519–S527.
17.
WearsRL. Advanced statistics: statistical methods for analyzing cluster and cluster-randomized data. Acad Emerg Med2002; 9: 330–341.
18.
DalmaijerESNordCLAstleDE. Statistical power for cluster analysis. BMC Bioinformatics2022; 23: 205.
19.
GalbraithSDanielJAVisselB. A study of clustered data and approaches to its analysis. J Neurosci2010; 30: 10601–10608.
20.
WoodmanRJMangoniAA. A comprehensive review of machine learning algorithms and their application in geriatric medicine: present and future. Aging Clin Exp Res2023; 35: 2363–2397.
21.
RichterANKhoshgoftaarTM. A review of statistical and machine learning methods for modeling cancer risk using structured clinical data. Artif Intell Med2018; 90: 1–14.
22.
WengSFRepsJKaiJ, et al.Can machine-learning improve cardiovascular risk prediction using routine clinical data?PloS One2017; 12: e0174944.
23.
Garre-OlmoJGarcia-PtacekSCalvó-PerxasL, et al.Diagnosis of dementia in the specialist setting: a comparison between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi). J Alzheimers Dis2016; 53: 1341–1351.
24.
ReligaDFereshtehnejadS-MCermakovaP, et al.Svedem, the Swedish Dementia Registry - A tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PloS One2015; 10: e0116538.
WettermarkBHammarNForedCM, et al.The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf2007; 16: 726–735.
XuHGarcia-PtacekSJönssonL, et al.Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology2021; 96: e2220–e2230.
30.
ThancharoenOLimwattananonCWaleekhachonloetO, et al.Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer’s disease: a network meta-analysis. Drugs Aging2019; 36: 435–452.
31.
LiD-DZhangY-HZhangW, et al.Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci2019; 13: 472.
32.
RaskindMAPeskindERTruyenL, et al.The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol2004; 61: 252–256.
33.
BullockR. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord2006; 20: 23–29.
34.
RobinsonDMKeatingGM. Memantine: a review of its use in Alzheimer’s disease. Drugs2006; 66: 1515–1534.
35.
SinghMAgarwalVPanchamP, et al. Exploring the role of statins in reversing the cognitive and neurovascular dysfunctions in dementia. In: AshrafGMUddinMS (eds) Current thoughts on dementia. Singapore: Springer, 2022, pp.417–440.
36.
YangZTohSLiX, et al.Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis. Eur J Epidemiol2022; 37: 615–627.
37.
HaagMDMHofmanAKoudstaalPJ, et al.Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry2009; 80: 13–17.
38.
OlmastroniEMolariGDe BeniN, et al.Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol2022; 29: 804–814.
39.
XuanKZhaoTQuG, et al.The efficacy of statins in the treatment of Alzheimer’s disease: a meta-analysis of randomized controlled trial. Neurol Sci2020; 41: 1391–1404.
40.
PolyTNIslamMWaltherBA, et al.Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology2020; 54: 214–226.
41.
BurgosJSBenavidesJDouilletP, et al.How statins could be evaluated successfully in clinical trials for Alzheimer’s disease?Am J Alzheimers Dis Demen2012; 27: 151–153.
42.
SiddiqiFHMenziesFMLopezA, et al.Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun2019; 10: 1817.
43.
MadhavanMHuTYGershBJ, et al.Efficacy of warfarin anticoagulation and incident dementia in a community-based cohort of atrial fibrillation. Mayo Clin Proc2018; 93: 145–154.
44.
KimDYangP-SJangE, et al.Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace2021; 23: 184–195.
45.
Da SilvaRMFLMirandaCMLiuT, et al.Atrial fibrillation and risk of dementia: epidemiology, mechanisms, and effect of anticoagulation. Front Neurosci2019; 13: 18.
46.
SubicACermakovaPReligaD, et al.Treatment of atrial fibrillation in patients with dementia: a cohort study from the Swedish Dementia Registry. J Alzheimers Dis2018; 61: 1119–1128.
47.
TopWMCKooyAStehouwerCDA. Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals (Basel)2022; 15: 312.
48.
SamarasKMakkarSCrawfordJD, et al.Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study. Diabetes Care2020; 43: 2691–2701.
49.
SecnikJXuHSchwertnerE, et al.The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia. Alzheimers Res Ther2021; 13: 197.
50.
BarberaMLehtisaloJPereraD, et al.A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol. Alzheimers Res Ther2024; 16: 23.
51.
RichardsonKLokeYKFoxC, et al.Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Med2020; 18: 351.
52.
EttchetoMOlloquequiJSánchez-LópezE, et al.Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci2019; 11: 44.
53.
LouzadaLLMachadoFVQuintasJL, et al.The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial. Neuropsychopharmacology2022; 47: 570–579.
54.
LouzadaLLMachadoFVNóbregaOT, et al.Zopiclone to treat insomnia in older adults: a systematic review. Eur Neuropsychopharmacol2021; 50: 75–92.
55.
APA Work Group on Alzheimer’s Disease and other Dementias, RabinsPVBlackerD, et al.American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry2007; 164: 5–56.
56.
RabinsPVRovnerBWRummansT, et al.Guideline Watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Focus Am Psychiatr Publ2017; 15: 110–128.
57.
TaipaleHKoponenMTanskanenA, et al.Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease. Int Clin Psychopharmacol2015; 30: 202–208.
58.
HessmannPDodelRBaumE, et al.Prescription of benzodiazepines and related drugs in patients with mild cognitive deficits and Alzheimer’s disease. Pharmacopsychiatry2019; 52: 84–91.
59.
SaarelainenLTolppanenA-MKoponenM, et al.Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. Int J Geriatr Psychiatry2018; 33: 583–590.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
